Nano Bridging Molecules SA

About Company

Nano Bridging Molecules S.A. ('NBM') is devoted to researching, developing, manufacturing, and marketing its patented SurfLink® range of advanced medical implant surface modifications designed to render medical implants biocompatible with the human body.

The company's technology has been developed over a 12 year period by a multi-disciplinary team from a number of renowned academic institutions including the University of Geneva, Ecole Polytechnique Federale de Lausanne, the University of Zurich and University of Berne. A university spin-off, NBM was incorporated in 2002, in 2008 it established new laboratories and offices in Canton Vaud, Switzerland, it currently employs 7 staff and has entered into over 65 contracts with various research institutions and other external service providers.

NBM's SurfLink® technology revolves around a concept pursuant to which a number of biological functions can be covalently bound to medical implant surfaces. The use of this advanced technology in implant operations promises to achieve :

• increased biocompatibility
• accelerated bone healing
• greatly enhanced implant fixation, and
• increased long term stability

NBM is currently focusing on its second large animal time course study (52 weeks, 24 animals) and a pilot dental clinical trial which is presently being expanded into a 3 - 5 centre dental clinical trial. The company will embark upon a C series funding round in Q1 2010. It aims to CE Mark its first dental implant surface treatment product in Q2 2010 and obtain FDA authorization to commence US sales in 2011.